Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27740912 | 0.90 | KDM4E (0.51) | AURKARPS6KB1PTGER1KDM4ELMNA | |
| SCHEMBL2360638 | 0.85 | AURKA (0.60) | AURKARPS6KB1PTGER1KDM4ELMNA | |
| SCHEMBL1899554 | 0.84 | CNR1 (0.43) | AURKARPS6KB1PTGER1KDM4ELMNA | |
| SCHEMBL10274481 | 0.84 | L3MBTL1 (0.45) | AURKARPS6KB1PTGER1KDM4ELMNA | |
| SCHEMBL17489117 | 0.83 | LMNA (0.47) | AURKARPS6KB1PTGER1LMNAPTGER3 | |
| SCHEMBL13659680 | 0.81 | PTGER1 (0.44) | AURKARPS6KB1PTGER1KDM4ELMNA | |
| SCHEMBL12050045 | 0.81 | CYP1A2 (0.45) | AURKARPS6KB1KDM4EEPHX2 | |
| SCHEMBL10274469 | 0.81 | BAZ2B (0.63) | AURKARPS6KB1PTGER1KDM4EEPHX2 | |
| SCHEMBL8017055 | 0.80 | LMNA (0.68) | AURKARPS6KB1PTGER1KDM4ELMNA | |
| SCHEMBL6078633 | 0.79 | GRN (0.53) | AURKARPS6KB1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| CN-108774214-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| CN-106928203-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | AURKA 47/4885RPS6KB1 187/4885PTGER1 1890/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | AURKA 47/4885RPS6KB1 187/4885PTGER1 1890/4885 |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | AURKA 1809/4885RPS6KB1 958/4885PTGER1 897/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | AURKA 1809/4885RPS6KB1 958/4885PTGER1 897/4885 |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | AURKA 47/4885RPS6KB1 187/4885PTGER1 1890/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | AURKA 47/4885RPS6KB1 187/4885PTGER1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.